Study Results. 7.1 Upon completion of the Requested Economic Planning Study, the NYISO will deliver the final written report of the completed Requested Economic Planning Study to Requestor, and, upon Requestor’s request, the Parties will meet at a mutually agreeable time and place to review the results of the Requested Economic Planning Study.
7.2 The NYISO will review the results of the Requested Economic Planning Studies to determine whether the results reveal Confidential Information that is not subject to disclosure under the NYISO’s Code of Conduct. Confidential Information will be removed or the results aggregated or masked sufficiently to avoid the disclosure of Confidential Information. The NYISO will post the results of the Requested Economic Planning Study on its website if and when it is required to do so in accordance with Section 31.3.3.10 of Attachment Y to the OATT.
Study Results. After analysis of Study Data from all sites is complete, CRO or Pfizer will provide Principal Investigator with a summary of the overall results of the Study. CRO and Pfizer encourage Principal Investigator to communicate the results, as appropriate, to the Study Subjects. If within two years after Study completion Pfizer identifies results that could affect Study Subject safety, CRO or Pfizer, in consultation with SUKL/the IRB/IEC as appropriate, will cooperate with Principal Investigator or Institution to ensure that those results are appropriately communicated to the Study Subjects by Principal Investigator or Institution.
Study Results. For purposes of clarity (a) the Parties hereby acknowledge and agree, in accordance with Section 1.77, that (1) all data and information obtained or produced in the conduct of the Feasibility Study and/or the Target Confirmation Study (the “Study Results”) shall be jointly owned by the Parties and (2) subject to subsection (b) below, neither Party shall cause or allow any Study Results to be published without the prior written consent of the other Party; and (b) notwithstanding anything to the contrary in Section 10.4, Section 1.77 or subsection (D)(a) above, on and after the date on which [***] becomes a Waived Target pursuant to this Agreement, (1) DICERNA shall solely own the Study Results and have the sole right to use such Study Results for any and all purposes, inside or outside of this Agreement, without restriction, (2) DICERNA shall be deemed to have granted KHK the right to use such Study Results solely for internal research purposes and (3) as between the Parties, DICERNA shall have the sole right to publish such Study Results; provided, that, (i) any contribution of KHK to the Study Results shall be duly recognized and co-authorship shall be determined in accordance with customary industry standards and (ii) to the extent that any such Study Results to be published contain any Confidential Information of KHK, including without limitation KHK [***] DDS Technology or KHK Program Technology, DICERNA shall obtain the prior written consent of KHK to such publication.
Study Results. Each Party shall designate a contact person to be primarily responsible for communicating with such person’s counterpart on all issues concerning the Initial Studies. Through such contact person, ViroPharma shall keep Schering reasonably informed on and involved in the progress of the Initial Studies, including by providing Schering with quarterly written status reports covering all of the Initial Studies. ViroPharma shall provide Schering with copies of all interim data and results generated from any of the Initial Studies, as well as all of the final data and results of each of the Initial Studies, including access to or copies of the database from each Interim Study in a format mutually agreeable to the Parties, promptly after they become available. All such data and results shall constitute Know-How, shall be treated as Confidential Information in accordance with Article 5, and shall only be used by Schering for the purpose of evaluating the Compound and the Product to determine whether or not to exercise the Option. The Parties acknowledge that the data and results from the Initial Studies are subject to disclosure to and use by Sanofi-Synthelabo as set forth in Section 3.3 of the SaSy Agreement.
Study Results. Following the Subscription Closing Date, the Corporation shall provide to the Investor a draft of any press release announcing the results of the Study, and shall consider, acting reasonably, any comments made by the Investor thereon; provided, however, that the Corporation shall not be required to provide such opportunity to comment in the event that, in the opinion of its outside legal counsel, the Corporation is required to make immediate disclosure of such results under Securities Laws. The foregoing right of the Investor shall terminate upon the earlier of: (a) the Investor’s Ownership Percentage falling below 5.0%; and (b) the later of (i) the date that is 18 months following the Subscription Closing Date and (ii) 6 months following completion of the Study; provided, however, that the Corporation and the Investor may mutually agree to extend the time periods referred to in (b) above by such additional period of time as may be agreed in writing between the Corporation and the Investor.
Study Results. InNexus will provide to CORIXA reports of the results for each of the experiments or studies InNexus conducts as outlined in Exhibit B, such reports to be provided to CORIXA in a timely manner following the completion of each experiment or study. Any and all reports communicated to CORIXA by InNexus within the scope of this Agreement, may be freely used by CORIXA but only for its own internal purposes. CORIXA will provide to InNexus reports of the results for each of the experiments or studies CORIXA conducts as outlined in Exhibit B, such reports to be provided to InNexus in a timely manner following the completion of each experiment or study. Any and all reports communicated to InNexus by CORIXA within the scope of this Agreement, may be freely used by InNexus for its own internal purposes.
Study Results. 8.1 Upon completion of the Additional Reliability Study, and payment by Requestor of any amount due pursuant to Section 7.3 of this Agreement, the NYISO will deliver the results of the completed Additional Reliability Study to Requestor, and the Parties will meet at a mutually agreeable time and place to review the results of the Additional Reliability Study.
8.2 The NYISO will review the results of the Additional Reliability Studies to determine whether the results reveal Confidential Information that is not subject to disclosure under the NYISO’s Code of Conduct. Confidential Information will be removed or the results aggregated or masked sufficiently to avoid the disclosure of Confidential Information. The NYISO will provide the results of the Additional Reliability Study to the Requestor. The NYISO will treat the Request for the Additional Reliability Study and the results of the Additional Reliability Study as Confidential Information in accordance with Attachment F to the OATT, and the NYISO will not include the results of the Additional Reliability Study in the Reliability Needs Assessment or Comprehensive Reliability Plan. Notwithstanding the foregoing, the Requestor acknowledges and agrees that the NYISO shall be free to conduct an independent analysis as part of the Comprehensive Reliability Planning Process if the NYISO determines, in its sole discretion, that such analysis is appropriate in light of the Additional Reliability Studies conducted. The Requestor further acknowledges and agrees that the NYISO will post the results of the Additional Reliability Study on its website if and when Requestor seeks regulated cost recovery under the OATT as an alternative regulated solution or regulated gap solution based upon the results of the Additional Reliability Study. Nothing in this Agreement shall be construed to limit the NYISO’s authority to determine the need for a regulated backstop solution.
Study Results. After analysis of Study Data from all sites is complete, Pfizer will provide Principal Investigator with a summary of the overall results of the Study. Pfizer encourage Principal Investigator to communicate the results, as appropriate, to the Study Subjects. If within two years after Study completion Xxxxxx identifies results that could affect Study Subject safety, Pfizer, in consultation with SUKL/the IRB/IEC as appropriate, will cooperate with Principal Investigator or Institution to ensure that those results are appropriately communicated to the Study Subjects by Principal Investigator or Institution.
Study Results. (a) Licensee hereby grants to Licensor a nonexclusive, royalty-free, right and license to use the Study Results (including the right to reference the Study Results in any filing with Regulatory Authorities) for research and development outside the Field and, at Licensor’s expense to prosecute any patents for Technology invented by Licensor and its Affiliates related to or resulting from the Study Results (the “Study Results Patents”) both inside and outside the Field which Study Results Patents and all Intellectual Property Rights in those Patent Rights shall be, and hereby are, owned by Licensor. For the avoidance of doubt, Study Results Patents, if issued, are licensed to Licensee in the Field pursuant to Section 2.1 of this Agreement.
(b) Upon Licensor’s request and as soon as practicable following completion of the Study, Licensee shall provide Licensor a copy of the Study Results and all Technology related to the Study Results. Licensor shall have the right to prosecute or apply for Study Results Patents, and Licensee shall execute, acknowledge and deliver such further documents and instruments and perform all such other acts as may be necessary or appropriate in order to effectuate this Section 2.4.
Study Results. 2.1 Ownership of records, Data and Intellectual Property SPONSOR shall own its case report forms and the data resulting from the Study. KFSH&RC shall own its medical records, research notebooks and related documentation and any intellectual property resulting from the Study subject to the option granted to SPONSOR to license Inventions in Section 2.3 below. KFSH&RC shall have the right to use the data for research, educational and patient care purposes, as well as to comply with any federal, state or local government laws or regulations. In recognition of SPONSOR’s legitimate business interest in keeping unpublished research results from being made available to its commercial competitors, KFSH&RC agree not to knowingly:
(a) disclose the research results to third party commercial entities in a form or in sufficient detail suitable for use to obtain pre-marketing approval from the FDA prior to a publication of the Study; nor
(b) provide the case report forms to third party commercial entities. Notwithstanding the above, SPONSOR shall not use any patient names, identifying information, photographs, or other likenesses without first obtaining the specific written informed consent of patient for such use.
